New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
The review article study the safety and efficacy of using direct acting oral anticoagulants: thrombin inhibitor dabigatran etexilate and inhibitors Xa of the blood clotting factor apixaban, rivaroxaban and edoxaban compared with the vitamin K antagonist warfarin in patients with non-valvular atrial...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2018-11-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/3080 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850030895189196800 |
|---|---|
| author | E. I. Baranova |
| author_facet | E. I. Baranova |
| author_sort | E. I. Baranova |
| collection | DOAJ |
| description | The review article study the safety and efficacy of using direct acting oral anticoagulants: thrombin inhibitor dabigatran etexilate and inhibitors Xa of the blood clotting factor apixaban, rivaroxaban and edoxaban compared with the vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation. The advantage of direct oral anticoagulants is emphasized. Particular attention is paid in the article to dabigatran etexilate, which demonstrated high efficacy and safety in randomized clinical trials and in actual clinical practice in patients with non-valvular atrial fibrillation. In addition, dabigatran etexilate in the composition of dual antiplatelet therapy in patients with coronary heart disease after stenting of the coronary arteries demonstrated greater safety than triple antithrombotic therapy, which included warfarin. The article shows indications for the use of dabigatran antagonist idaruzizumab and the method of its administration. |
| format | Article |
| id | doaj-art-2a6effc144dd452db022a2295fdee1ec |
| institution | DOAJ |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| publishDate | 2018-11-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj-art-2a6effc144dd452db022a2295fdee1ec2025-08-20T02:59:07Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202018-11-0101013614410.15829/1560-4071-2018-10-136-1442536New safety standards for anticoagulant therapy in the treatment of atrial fibrillationE. I. Baranova0Pavlov First Saint-Petersburg State Medical University of the Ministry of Health; Almazov National Medical Research Center of the Ministry of HealthThe review article study the safety and efficacy of using direct acting oral anticoagulants: thrombin inhibitor dabigatran etexilate and inhibitors Xa of the blood clotting factor apixaban, rivaroxaban and edoxaban compared with the vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation. The advantage of direct oral anticoagulants is emphasized. Particular attention is paid in the article to dabigatran etexilate, which demonstrated high efficacy and safety in randomized clinical trials and in actual clinical practice in patients with non-valvular atrial fibrillation. In addition, dabigatran etexilate in the composition of dual antiplatelet therapy in patients with coronary heart disease after stenting of the coronary arteries demonstrated greater safety than triple antithrombotic therapy, which included warfarin. The article shows indications for the use of dabigatran antagonist idaruzizumab and the method of its administration.https://russjcardiol.elpub.ru/jour/article/view/3080direct oral anticoagulantsatrial fibrillationdabigatran etexilateidarucizumab |
| spellingShingle | E. I. Baranova New safety standards for anticoagulant therapy in the treatment of atrial fibrillation Российский кардиологический журнал direct oral anticoagulants atrial fibrillation dabigatran etexilate idarucizumab |
| title | New safety standards for anticoagulant therapy in the treatment of atrial fibrillation |
| title_full | New safety standards for anticoagulant therapy in the treatment of atrial fibrillation |
| title_fullStr | New safety standards for anticoagulant therapy in the treatment of atrial fibrillation |
| title_full_unstemmed | New safety standards for anticoagulant therapy in the treatment of atrial fibrillation |
| title_short | New safety standards for anticoagulant therapy in the treatment of atrial fibrillation |
| title_sort | new safety standards for anticoagulant therapy in the treatment of atrial fibrillation |
| topic | direct oral anticoagulants atrial fibrillation dabigatran etexilate idarucizumab |
| url | https://russjcardiol.elpub.ru/jour/article/view/3080 |
| work_keys_str_mv | AT eibaranova newsafetystandardsforanticoagulanttherapyinthetreatmentofatrialfibrillation |